After Your Patients With PSMA+ mCRPC Receive Their First ARPI, Be Ready for What's Next1
Identifying Patients
1 ARPI could have been received at any point in your patient’s prostate cancer journey, including in the castration-sensitive setting1,2
For your patients on ARPI, at what point do you begin considering subsequent treatment options?
ARPI, androgen receptor pathway inhibitor; CRPC, castration-resistant prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.
Patient Profiles
MEET PATIENTS WITH PSMA+ mCRPC WHO ARE ELIGIBLE FOR PLUVICTO
Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey1,2
Hypothetical patient cases.
Which of your patients with PSMA+ mCRPC could benefit from PLUVICTO now?
ADT, androgen deprivation therapy; EBRT, external beam radiation therapy; mCSPC, metastatic castration-sensitive prostate cancer; nmCSPC, nonmetastatic castration-sensitive prostate cancer.